The Whipsaw Nobody Is Talking About

The FDA rejected Moderna's mRNA flu vaccine application. Then, one week later, it agreed to review it anyway.

A federal agency reversed itself in seven days. Most mainstream coverage either buried that detail or framed the reversal as a clean win.

What Actually Happened

Moderna submitted an application for its mRNA-based influenza vaccine — what would be the first flu shot using the same messenger RNA technology behind its COVID-19 shots. The company's phase 3 trial enrolled more than 40,000 adults aged 50 and older, according to CIDRAP News.

The FDA's Center for Biologics Evaluation and Research (CBER) refused to review it. The stated reason: Moderna's trial comparator vaccine was not the "best-available standard of care" for older adults. Regulators wanted the study to measure against a higher-dose flu vaccine for seniors.

According to virologist Angela Rasmussen, PhD, of the University of Saskatchewan, the trial design Moderna used is "essentially the trial design that every single flu vaccine has used," as she told CIDRAP News directly.

According to CIDRAP, the FDA's own prior correspondence with Moderna explicitly stated, "We agree it would be acceptable to use a licensed standard dose influenza vaccine as the comparator in your Phase 3 study." The agency blessed the design. Then rejected the application for failing to meet a standard the agency itself said was acceptable.

Neither federal drug study regulations nor the FDA's own guidance for flu vaccines even contain the phrase "best-available standard of care" in the context of selecting a comparator vaccine, according to CIDRAP.

Moderna Was NOT Happy

Moderna CEO Stéphane Bancel said in a press release that the CBER decision "did not identify any safety or efficacy concerns" with the product. He called the refusal inconsistent with the goal of keeping America at the forefront of medical innovation.

Moderna's president Stephen Hoge, MD, told The New York Times he was surprised and confused — pointing to the FDA's earlier support for the study design.

Peter Hotez, MD, PhD, of Baylor College of Medicine, told CIDRAP News: "There was a commitment." He said stringing a company along and then suddenly refusing to even review the application undermines the entire framework vaccine makers rely on when designing trials.

The mRNA flu vaccine has already been accepted for review in the European Union, Canada, and Australia, according to CIDRAP. The U.S. is now behind.

The Reversal

Within a week, the FDA flipped. According to The Cardiology Advisor, the agency agreed to review Moderna's application after Moderna modified its approach.

The new plan splits the approval strategy by age group. Moderna is now seeking full approval for adults aged 50 to 64. For adults aged 65 and older, it's seeking accelerated approval — a faster pathway that gets products to market based on early data while additional research continues. Moderna committed to a post-marketing study for seniors to address the FDA's original concerns, per The Cardiology Advisor.

The FDA advisory panel is scheduled for June 18, according to Benzinga, citing a Bloomberg report of the formal notice. The FDA's final decision deadline is August 5, according to The Cardiology Advisor — leaving enough runway to distribute vaccines before the fall respiratory virus season.

What the Record Shows

Most outlets treated the reversal as straightforward resolution. "FDA agrees to review vaccine" — clean headline, move on.

The core question remains unanswered: why did the FDA reject a trial design it had previously approved in writing? The agency never explained that publicly. No CBER official has been named in connection with the initial rejection. No one has been held accountable for the reversal.

The Hill framed the advisory panel scheduling as a sign of "a more stable approach to drug reviews" after recent personnel upheaval at the FDA. Rejecting an application based on a standard you never formally defined, then reversing within a week, does not suggest regulatory stability.

This happened against the backdrop of real turbulence at the FDA — including firings and leadership changes under the current administration. Whether political pressure, bureaucratic confusion, or a genuine regulatory dispute drove the initial rejection remains unclear. The agency has not explained it. Most media outlets have moved on.

What This Means for Regular People

If the FDA clears the vaccine by August 5, Americans aged 50 and older could have access to an mRNA flu shot before this coming flu season. That's a real option — mRNA technology can be updated faster than traditional vaccines and may offer improved efficacy.

But this episode raises a larger question about regulatory process: the FDA made a commitment to a company, broke it, could not defend the new standard it invented, and then quietly reversed course. The agency gave no one — companies, doctors, or patients — a straight answer about why.

If the FDA can move the goalposts mid-trial on a flu vaccine, it can do it on anything.